DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Mehnert JM, Bergsland E, O’Neil BH. et al.
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study.
Cancer 2020;
126 (13) 3021-3030
We do not assume any responsibility for the contents of the web pages of other providers.